Targeting cellular energy production in neurological disorders

Expert Opinion on Investigational Drugs

Volumn 12, Issue 10, 2003, Pages 1655-1679

  Baker, Steven K ^a   Tarnopolsky, Mark A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

lipoic acid; OH methylbutyrate; Amyotrophic lateral sclerosis; Coenzyme; Creatine; Energy; Friedreich's ataxia; Huntington's Mitochondrial cytopathies; Neuromuscmular diseases; Neuroprotection; Nicotinamide; Parkinson's disease; Q10; Reactive oxygen species; Riboflavin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYLBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ASCORBIC ACID; CITRATE SYNTHASE; CREATINE; CREATINE KINASE; CYANOCOBALAMIN; CYTOCHROME C OXIDASE; DIZOCILPINE; DRUG DERIVATIVE; GLUTAMIC ACID; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDEBENONE; MALONIC ACID; MINOCYCLINE; NEUROPROTECTIVE AGENT; NEUROTOXIN; NICOTINAMIDE; PANTOTHENIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REMACEMIDE; RIBOFLAVIN; RILUZOLE; THIOCTIC ACID; TRACE ELEMENT; UBIDECARENONE; UBIQUINONE; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; APOPTOSIS; BIOENERGY; BRAIN; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL DEATH; CELL ENERGY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; ENERGY METABOLISM; ENERGY YIELD; ENZYME DEFECT; EPHEDRA SINICA; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; ISCHEMIA; KIDNEY DISEASE; METABOLIC PARAMETERS; METABOLISM; MOUSE; MUSCLE; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; RAT; REVIEW; STROKE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CREATINE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; HUMANS; HUNTINGTON DISEASE; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; UBIQUINONE;

EID: 0142210297     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.10.1655     Document Type: Review

References (330)

1. LUFT R, IKKOS D, PALMIERI G, ERNSTER L, AFZELIUS B: A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J. Clin. Invest. (1962) 41:1776-1804.
2. SIMON DK, JOHNS DR: Mitochondrial disorders: clinical and genetic features. Ann. Rev. Med. (1999) 50:111-127.
3. SIMON DK, LIN MT, AHN CH et al.: Low mutational burden of individual acquired mitochondrial DNA mutations in brain. Genomics (2001) 73(1):113-116.
4. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell (1997) 89:93-103.
5. GREEN DR, REED JC: Mitochondria and apoptosis. Science (1998) 281:1309-1312.
6. PENG TI, JOU MJ, SHEU SS, GREENAMYRE JT: Visualization of NMDA receptor-induced mitochondrial calcium accumulation in striatal neurons. Exp. Neurol. (1998) 149:1-12.
7. MCLENNAN HR, DEGLI ESPOSTI M: The contribution of mitochondrial respiratory complexes to the production of reactive oxygenspecies. J. Bioenerg. Biomembr. (2000) 32(2):153-162.
8. GENOVA ML, VENTURA B, GIULIANO G et al.: The site of production of superoxide radical in mitochondrial complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2. FEBS Lett. (2001) 505(3):364-368.
9. RICHTER C: Do mitochondrial DNA fragments promote cancer and aging? FEBS Lett. (1988) 241(1-2):1-5.
10. CHANCE C, SIES H, BOVERIS A: Hydroperoxide metabolism in mammalian organs. Physiol. Rev. (1979) 59(3):527-605.
11. DOHERTY TJ, LOUGHEED K, MARKEZ J, TARNOPOLSKY MA: Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Neurology (2001) 57(3):559-560.
12. DERAVE W, EIJNDE BO, HESPEL P: Creatine supplementation in health and disease: what is the evidence for long-term efficacy? Mol. Cell. Biochem. (2003) 244(1-2):49-55.
13. WYSS M, KADDURAH-DAOUK R: Creatine and creatinine metabolism. Physiol. Rev. (2000) 80(3):1107-1213.
14. GUTHMILLER P, VAN PILSUM JF, BOEN JR, MCGUIRE DM: Cloning and sequencing of rat kidney L-arginine:glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. J. Biol. Chem. (1994) 269(26):17556-17560.
15. WALKER JB: Creatine: biosynthesis, regulation, and function. Adv. Enzymol. Relat. Areas Mol. Biol. (1979) 50:177-242.
16. SIPILA I: Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia. Biochim. Biophys. Acta (1980) 613(1):79-84.
17. SANDBERG AA, HECHT HH, TYLER FH: studies in disorders of muscle. X. The site of creatine synthesis in the human. Metabolism (1953) 2:22-29.
18. SORA I, RICHMAN J, SANTORO G et al.: The cloning and expression of a human creatine transporter. Biochem. Biophys. Res. Commun. (1994) 204:419-427.
19. BRAULT JJ, TERJUNG RL: Creatine uptake and creatine transporter expression among rat skeletal muscle fiber types. Am. J. Physiol. Cell Physiol. (2003) 284(6):C1481-C1489.
20. STEENGE GR, LAMBOURNE J, CASEY A et al: Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. Am. J. Physiol. (1998) 275:E974-E979.
21. WILLOT CA, YOUNG ME, LEIGHTON B et al.: Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin. Acta Physiol. Scand. (1999) 166(2):99-104.
22. ODOOM JE, KEMP GJ, RADDA GK: The regulation of total creatine content in a myoblast cell line. Mol. Cell. Biochem. (1996) 158(2):179-188.
23. LOIKE JD, ZALUTSKY DL, KABACK E et al.: Extracellular creatine regulates creatine transport in rat and human muscle cell. Proc. Natl. Acad. Sci. USA (1988) 85:807-811.
24. GUERRERO-ONTIVEROS ML, WALLIMANN T: Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol. Cell. Biochem. (1998) 184:427-437.
25. TARNOPOLSKY MA, PARISE G, FU MH et al.: Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans. Mol. Cell. Biochem. (2003) 244(1-2):159-166.
26. TRAN TT, DAI W, SARKAR HK: Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter. J. Biol. Chem. (2000) 275(46):35708-35714.
27. BREIL M, CHARIOT P: Muscle disorders associated with cyclosporine treatment. Muscle Nerve (1999) 22(12):1631-1636.
28. BOGDANIS GC, NEVILL ME, BOOBIS LH, LAKOMY HK: Contribution of phosphocreatine and aerobic metabolism to energy supply during repeated sprint exercise. J. Appl. Physiol. (1996) 80:876-884.
29. BOGDANIS GC, NEVILL ME, BOOBIS LH et al.: Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man. J. Physiol. (Lond.) (1995) 482:467-480.
30. SAHLIN K, HARRIS RC, HULTMAN E: Resynthesis of creatine phosphate in human muscle after exercise in relation to intramuscular pH and availability of oxygen. Scand. J. Clin. Lab. Invest. (1979) 39:551-558.
31. MATTHEWS PM, ALLAIRE C, SHOUBRIDGE EA et al: In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology (1991) 41:114-120.
32. RADDA GK, TAYLOR DJ, ARNOLD DL: Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Biochem. Soc. Trans. (1985) 13:654.
33. KAMINSKY P, ROBIN-LHERBIER B, BRUNOTTE F et al.: Energetic metabolism in hypothyroid skeletal muscle, as studied by phosphorus magnetic resonancespectroscopy. J. Clin. Endocrinol. Metab. (1992) 74(1):124-129.
34. SMITH CD, AIN KB: Brain metabolism in hypothyroidism studied with 31P magnetic-resonance spectroscopy. Lancet (1995) 345(8950):619-620.
35. WESTERBLAD H, LANNERGREN J: Reduced maximum shortening velocity in the absence of phosphocreatine observed in intact fibres of Xenopus skeletal muscle. J. Physiol. (Lond.) (1995) 482:383-390.
36. KUROSAWA Y, HAMAOKA T, KATSUMURA T et al.: Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise. Mol. Cell. Biochem. (2003) 244(1-2):105-112.
37. CASEY A, GREENHAFF PL: Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am. J. Clin. Nutr. (2000) 72(Suppl. 2):607S-617S.
38. KALDIS P, HEMMER W, ZANOLLA E et al.: 'Hot spots' of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. Dev. Neurosci. (1996) 18:542-554.
39. KEKELIDZE T, KHAIT I, TOGLIATTI A, HOLTZMAN D: Brain creatine kinase and creatine transporter proteins in normal and creatine-treated rabbit pups. Dev. Neurosci. (2000) 22(5-6):437-443.
40. CHEN L, ROBERTS R, FRIEDMAN DL: Expression of brain-type creatine kinase and ubiquitous mitochondrial creatine kinase in the fetal rat brain: evidence for a nuclear energy shuttle. J. Comp. Neurol. (1995) 363(3):389-401.
41. DA SILVA CG, BUENO AR, SCHUCK PF et al.: L-2-hydroxyglutaric acid inhibits mitochondrial creatine kinase activity from cerebellum of developing rats. Int. J. Dev. Neurosci. (2003) 21(4):217-224.
42. STADHOUDERS AM, JAP PH, WINKLER HP et al.: Mitochondrial creatine kinase: a major constituent of pathological inclusions seen in mitochondrial myopathies. Proc. Natl. Acad. Sci. USA (1994) 91:5089-5093.
43. BRDICZKA D, WALLIMANN T: The importance of the outer mitochondrial compartment in regulation of energy metabolism. Mol. Cell. Biochem. (1994) 133-134:69-83.
44. ROJO M, HOVIUS R, DEMEL RA et al.: Mitochondrial creatine kinase mediates contact formation between mitochondrial membranes. J. Biol. Chem. (1991) 266:20290-20295.
45. SCHLATTNER U, DOLDER M, WALLIMANN T, TOKARSKA-SCHLATTNER M: Mitochondrial creatine kinase and mitochondrial outer membrane porin show a direct interaction that is modulated by calcium. J. Biol. Chem. (2001) 276(51):48027-48030.
46. BRDICZKA D, BEUTNER G, RUCK A et al.: The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Biofactors (1998) 8:235-242.
47. HAN D, ANTUNES F, DANERI F, CADENAS E: Mitochondrial superoxide anion production and release into intermembrane space. Methods Enzymol. (2002) 349:271-280.
48. KONOREV EA, HOGG N, KALYANARAMAN B: Rapid and irreversible inhibition of creatine kinase by peroxynitrite. FEBS Lett. (1998) 427(2):171-174.
49. WENDT S, SCHLATTNER U, WALLIMANN T: Differential effects of peroxynitrite on human mitochondrial creatine kinase isoenzymes. Inactivation, octamer destabilization, and identification of involved residues. J. Biol. Chem. (2003) 278(2):1125-1130.
50. STACHOWIAK O, DOLDER M, WALLIMANN T, RICHTER C: Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J. Biol. Chem. (1998) 273:16694-16699.
51. O'GORMAN E, BEUTNER G, DOLDER M, KORETSKY AP, BRDICKA D, WALLIMANN T: The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. (1997) 414(2):253-257.
52. ARSTALL MA, BAILEY C, GROSS WL, BAK M, BALLIGAND J-L, KELLY RA: Reversible S-nitrosation of creatine kinase by nitric oxide in adult rat ventricular myocytes. J. Mol. Cell Cardiol. (1998) 30(5):979-988.
53. KAASIK A, MINAJEVA A, DE SOUSA E, VENTURA-CLAPIER R, VEKSLER V: nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase. FEBS Lett. (1999) 444(1):75-77.
54. WALSH B, TONKONOGI M, SODERLUND K, HULTMAN E, SAKS V, SAHLIN K: The role of phosphorylcreatine and creatine in the regulation of mitochondrial respiration in human skeletal muscle. J. Physiol. (2001) 537(Pt 3):971-978.
55. BROSNAN MJ, CHEN LH, WHEELER CE, VAN DYKE TA, KORETSKY AP: Phosphocreatine protects ATP from a fructose load in transgenic mouse liver expressing creatine kinase. Am. J. Physiol. (1991) 260(6, Pt 1):C1191-C1200.
56. MILLER K, HALOW J, KORETSKY AP: Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am. J. Physiol. (1993) 265(6, Pt 1):C1544-C1551.
57. DOLDER M, WALZEL B, SPEER O, SCHLATTNER U, WALLIMANN T: Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J. Biol. Chem. (2003) 278(20):17760-17766.
58. O'GORMAN E, PIENDL T, MULLER M et al.: Mitochondrial intermembrane inclusion bodies: the common denominator between human mitochondrial myopathies and creatine depletion, due to impairment of cellular energetics. Mol. Cell. Biochem. (1997) 174:283-289.
59. O'GORMAN E, FUCHS KH, TITTMANN P et al.: Crystalline mitochondrial inclusion bodies isolated from creatine depleted rat soleus muscle. J. Cell Sci. (1997) 110:1403-1411.
60. TARNOPOLSKY MA, CHORNEYKO K, SIMON D, JOHNS D: Reversal of paracrystalline inclusions in a patient with a G15497A missense mutation following creatine monohydrate supplementation. Mitochondrial Interest Group Minisymposium (Mitochondria: Interaction of Two Genomes), NIH, Bethesda, USA (2000).
61. KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat. Med. (1998) 5:347-350.
62. LAWLER JM, BARNES WS, WU G, SONG W, DEMAREE S: Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. (2002) 290(1):47-52.
63. 2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. (1998) 439:357-362.
64. KOUFEN P, RUCK A, BRDICZKA D et al.: Free radical-induced inactivation of creatine kinase: influence on the octameric and dimeric states of the mitochondrial enzyme (Mib-CK). Biochem. J. (1999) 344(Pt 2):413-417.
65. INGWALL JS: Creatine and the control of muscle-specific protein synthesis in cardiac and skeletal muscle. Circ. Res. (1976) 38:I115-I123.
66. INGWALL JS, WEINER CD, MORALES MF et al.: Specificity of creatine in the control of muscle protein synthesis. J. Cell Biol. (1974) 62:145-151.
67. WILLOUGHBY DA, ROSENE JM: Effects of oral creatine and resistance training on myogenic regulatory factor expression. Med. Sci. Sports Exerc. (2003) 35(6):923-929.
68. EARNEST CP, SNELL PG, RODRIGUEZ R et al.: The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. Acta Physiol. Scand. (1995) 153:207-209.
69. MIHIC S, MACDONALD JR, MCKENZIE S, TARNOPOLSKY MA: Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med. Sci. Sports Exerc. (2000) 32:291-296.
70. PARISE G, MIHIC S, MACLENNAN D, YARESHESKI KE, TARNOPOLSKY MA: Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J. Appl. Physiol. (2001) 91(3):1041-1047.
71. DANGOTT B, SCHULTZ E, MOZDZIAK PE: Dietary creatine monohydrate supplementation increases satellite cell mitotic activity during compensatory hypertrophy. Int. J. Sports Med. (2000) 21:13-16.
72. VIERCK JL, ICENOGGLE DL, BUCCI L, DODSON MV: The effects of ergogenic compounds on myogenic satellite cells. Med. Sci. Sports Exerc. (2003) 35(5):769-76.
73. 2+ store in skeletal muscle. J. Biol. Chem. (2002) 277(7):5275-5284.
74. VAN LEEMPUTTE M, VANDENBERGHE K, HESPEL P: Shortening of muscle relaxation time after creatine loading. J. Appl. Physiol. (1999) 86:840-844.
75. GOMEZ-ANGELATS M, CIDLOWSKI JA: Cell volume control and signal transduction in apoptosis. Toxicol. Pathol. (2002) 30(5):541-551.
76. SCHULZE A: Creatine deficiency syndromes. Mol. Cell. Biochem. (2003) 244(1-2):143-150.
77. LEUZZI V: Inborn errors of creatine metabolism and epilepsy: clinical features, diagnosis, and treatment. J. Child Neurol. (2002) 17(Suppl. 3):3S89-3S97.
78. STOCKLER S, ISBRANDT D, HANEFELD F, SCHMIDT B, VON FIGURA K: Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man. Am. J. Hum. Genet. (1996) 58(5):914-922.
79. ITEM CB, STOCKLER-IPSIROGLU S, STROMBERGER C et al.: Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am. J. Hum. Genet. (2001) 69(5):1127-1133.
80. STOCKLER S, HANEFELD F, FRAHM J: Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet (1996) 348(9030):789-790.
81. STOCKLER S, HOLZBACH U, HANEFELD F et al.: Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr. Res. (1994) 36(3):409-413.
82. LEUZZI V, BIANCHI MC, TOSETTI M et al.: Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with creatine supplementation). Neurology (2000) 55(9):1407-1409.
83. SCHULZE A, BACHERT P, SCHLEMMER H et al.: Lack of creatine in muscle and brain in an adult with GAMT deficiency. Ann. Neurol. (2003) 53(2):248-251.
84. SALOMONS GS, VAN DOOREN SJ, VERHOEVEN NM et al.: X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am. J. Hum. Genet. (2001) 68(6):1497-1500.
85. DEGRAUW TJ, CECIL KM, BYARS AW, SALOMONS GS, BALL WS, JAKOBS C: The clinical syndrome of creatine transporter deficiency. Mol. Cell. Biochem. (2003) 244(1-2):45-48.
86. HOLTZMAN D, MCFARLAND E, MOERLAND T, KOUTCHER J, KUSHMERICK MJ, NEURINGER LJ: Brain creatine phosphate and creatine kinase in mice fed an analogue of creatine. Brain Res. (1989) 483(1):68-77.
87. WOOD IS, TRAYHURN P: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr. (2003) 89(1):3-9.
88. BONEN A: The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur. J. Appl. Physiol. (2001) 86(1):6-11.
89. SMITH CD, AIN KB: Brain metabolism in hypothyroidism studied with 31P magnetic-resonance spectroscopy. Lancet (1995) 345(8950):619-620.
90. 12 on formation of creatine in vitro and in vivo. Nature (1951) 167:1067-1068.
91. VAN PILSUM JF, WAHMAN RE: Creatine and creatinine in the carcass and urine of vitamin E-deficient rabbits. J. Biol. Chem. (1960) 235:2092-2094.
92. KIM GS, CHEVLI KD, FITCH CD: Fasting modulates creatine entry into skeletal muscle in the mouse. Experimentia (1983) 39:1360-1362.
93. HOBERMAN HD, SIMS EAH, ENGSTROM WW: The effect of methyltestosterone on the rate of synthesis of creatine. J. Biol. Chem. (1948) 173:111-116.
94. SIPILA I, RAPOLA J, SIMELL O, VANNAS A: Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. N. Engl. J. Med. (1981) 304:867-870.
95. BRODY LC, MITCHELL GA, OBIE C et al.: Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences. J. Biol. Chem. (1992) 267(5):3302-3307.
96. NANTO-SALONEN K, KOMU M, LUNDBOM N et al.: Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia. Neurology (1999) 53:303-307.
97. 31P spectrum in gyrate atrophy with hyperornithinaemia. Eur. J. Clin. Invest. (1999) 29:1060-1065.
98. VANNAS-SULONEN K, SIPILA I, VANNAS A et al.: Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation. Ophthalmology (1985) 92:1719-1727.
99. HAND CK, ROULEAU GA: Familial amyotrophic lateral sclerosis. Muscle Nerve (2002) 25(2):135-159.
100. KONG J, XU Z: Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. (1998) 18(9):3241-3250.
101. BEAL MF: Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. (2003) 53(Suppl. 3):S39-S47.
102. MATTHEWS RT, FERRANTE RJ, KLIVENYI P et al: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. (1999) 157(1):142-149.
103. MATTHEWS RT, YANG L, JENKINS BG et al.: Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. (1998) 18(1):156-163.
104. ANDREASSEN OA, JENKINS BG, DEDEOGLU A et al.: Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. (2001) 77(2):383-390.
105. XU CJ, KLUNK WE, KANFER JN et al.: Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J. Biol. Chem. (1996) 271:13435-13440.
106. BREWER GJ, WALLIMANN TW: Protective effect of the energy precursor creatine against toxicity of glutamate and β-amyloid in rat hippocampal neurons. J. Neurochem. (2000) 74:1968-1978.
107. IKEDA K, IWASAKI Y, KINOSHITA M: Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2000) 1(3):207-212.
108. SNOW RJ, TURNBULL J, DA SILVA S, JIANG F, TARNOPOLSKY MA: Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience (2003) 119(3):661-667.
109. ZHANG W, NARAYANAN M, FRIEDLANDER RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. (2003) 53(2):267-270.
110. 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology (2001) 43(3):189-197.
111. MAZZINI L, BALZARINI C, COLOMBO R et al.: Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J. Neurol. Sci. (2001) 191(1-2):139-144.
112. GROENEVELD JG, VELDINK JH, VAN DER TWEEL I et al.: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. (2003) 53(4):437-445.
113. DRORY VE, GROSS D: No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2002) 3(1):43-46.
114. THE HUNTINGTON'S DISEASE COLLABORATIVE RESEARCH GROUP: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell (1993) 72:971-983.
115. GU M, GASH MT, MANN VM, JAVOY-AGIG F, COOPER JM, SCHAPIRA AH: Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. (1996) 39(3):385-389.
116. BROWNE SE, BOWLING AC, MACGARVEY U et al.: Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. (1997) 41(5):646-653.
117. JENKINS B, KOROSHETZ W, BEAL MF, ROSEN B: Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology (1993) 43(12):2689-2695.
118. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology (1998) 50(5):1357-1365.
119. KOROSHETZ WJ, JENKINS BG, ROSAS HD, BEAL MF: Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. (1997) 41(2):160-165.
120. LODI R, SCHAPIRA AH, MANNERS D et al.: Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. (2000) 48(1):72-76.
121. BEAL MF, BROUILLET E, JENKINS B, HENSHAW R, ROSEN B, HYMAN BT: Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. (1993) 61(3):1147-1150.
122. BOGDANOV MB, FERRANTE RJ, KUEMMEREL S, KLIVENYI P, BEAL MF: Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. (1998) 71(6):2642-2644.
123. 1H MRS changes in Huntington's disease. Neurology (1999) 53(4):806-812.
124. 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology (1998) 50(4):1033-1040.
125. 1H NMR spectroscopy. J. Neurosci. Res. (2001) 66(5 ):891-898.
126. SHEAR DA, HAIK KL, DUNBAR GL: Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport (2000) 11(9):1833-1837.
127. FERRANTE RJ, ANDREASSEN OA, JENKINS BJ et al.: Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. (2000) 20(12):4389-4397.
128. ANDREASSEN OA, DEDEOGLU A, FERRANTE RJ et al.: Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. (2001) 8(3):479-491.
129. DEDEOGLU A, KUBILUS JK, YANG L et al.: Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. (2003) 85(6):1359-1367.
130. MALCON C, KADDURAH-DAOUK R, BEAL MF: Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res. (2000) 860(1-2):195-198.
131. KIEBURTZ K, HUNTINGTON STUDY GROUP: Placebo-controlled trial of creatine in HD. Neurology (2001) 56(Suppl. 3):A386.
132. VERBESSEM P, HESPEL P, DOM R: Oral creatine supplementation in patients with Huntington's disease. Neurology (2002) 58(Suppl. 7):A334.
133. TABRIZI SJ, BLAMIRE AM, MANNERS DN et al.: Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. Neurology (2003) 61(1):141-142.
134. MARDER K, ZHAO H, MYERS RH et al.: Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 54(2):452-458.
135. KLOPSTOCK T, SCHLAMP V, SCHMIDT F et al.: Creatine monohydrate in mitochondrial diseases: a double-blind, placebo-controlled, cross-over study in 16 patients with chronic progressive external opthalmolegia or mitochondrial myopathy. Neurology (1999) 52:A543-A544.
136. TARNOPOLSKY MA, ROY BD, MACDONALD JR: A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve (1997) 20(12):1502-1509.
137. BORCHERT A, WILICHOWSKI E, HANEFELD F: Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle Nerve (1999) 22:1299-1300.
138. HAGENFELDT L, VON DOBELN U, SOLDERS G, KAIJSER L: Creatine treatment in MELAS. Muscle Nerve (1994) 17(10):1236-1237.
139. BARISIC N, BERNERT G, IPSIROGLU O et al.: Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics (2002) 33(3):157-161.
140. KOMURA K, HOBBIEBRUNKEN E, WILICHOWSKI EK, HANEFELD FA: Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr. Neurol. (2003) 28(1):53-58.
141. TARNOPOLSKY MA, PARISE G: Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve (1999) 22:1228-1233.
142. WALTER MC, LOCHMULLER H, REILICH P et al.: Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology (2000) 54:1848-1850.
143. 31P magnetic resonance spectroscopy study. Neurol. Res. (2000) 22(2):145-150.
144. LOUIS M, LEBACQ J, POORTMANS JR et al.: Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve (2003) 27(5):604-610.
145. WALTER MC, REILICH P, LOCHMULLER H et al.: Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J. Neurol. (2002) 249(12):1717-1722.
146. SCHNEIDER-GOLD C, BECK M, WESSIG C et al.: Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology (2003) 60(3):500-502.
147. TARNOPOLSKY M, MARTIN J: Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology (1999b) 52:854-857.
148. VORGERD M, GREHL T, JAGER M et al.: Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch. Neurol. (2000) 57:956-963.
149. VOGERD M, ZANGE J, KLEY R et al.: Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch. Neurol. (2002) 59(1):97-101.
150. BARNES PRJ, KEMP GJ, TAYLOR DJ, RADDA GK: Skeletal muscle metabolism in myotonic dystrophy. Brain (1997) 120:1699-1711.
151. KEMP GJ, TAYLOR GJ, DUNN JF, FROSTICK SP, RADDA GK: Cellular energetics of dystrophic muscle. J. Neurol. Sci. (1993) 116:201-206.
152. OP'T EIJNDE B, RICHTER EA, HENQUIN JC, KIENS B, HESPEL P: Effect of creatine supplementation on creatine and glycogen content in rat skeletal muscle. Acta Physiol. Scand. (2001) 171(2):169-176.
153. NELSON AG, ARNALL DA, KOKKONEN J, DAY R, EVANS J: Muscle glycogen supercompensation is enhanced by prior creatine supplementation. Med. Sci. Sports Exerc. (2001) 33(7):1096-1100.
154. O'REILLY DS, CARTER R, BELL E, HINNIE J, GALLOWAY PJ: Exercise to exhaustion in the second-wind phase of exercise in a case of McArdle's disease with and without creatine supplementation. Scott. Med. J. (2003) 48(2):46-48.
155. PARODI M, REBAUDO R, PERASSO L, GANDOLFO C, CUPELLO A, BALESTRINO M: Effects of exogenous creatine on population spike amplitude and on postanoxic hyperexcitability in brain slices. Brain Res. (2003) 963(1-2):197-202.
156. BALESTRINO M, LENSMAN M, PARODI M et al: Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids (2002) 23(1-3):221-229.
157. WILKEN B, RAMIREZ JM, PROBST I, RICHTER DW, HANEFELD F: Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch. Dis. Child Fetal Neonatal Ed. (2000) 82(3):F224-F227.
158. ADCOCK KH, NEDELCU J, LEONNEKER T, MARTIN E, WALLIMANN T, WAGNER BP: Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev. Neurosci. (2002) 24(5):382-388.
159. MICHAELIS T, WICK M, FUJIMORI H, MATSUMURA A, FRAHM J: Proton MRS of oral creatine supplementation in rats. Cerebral metabolite concentrations and ischemic challenge. NMR Biomed. (1999) 12(5):309-314.
160. HAUSMANN ON, FOUAD K, WALLIMANN T, SCHWAB ME: Protective effects of oral creatine supplementation on spinal cord injury in rats. Spinal Cord (2002) 40(9):449-456.
161. SULLIVAN PG, GEIGER JD, MATTSON MP, SCHEFF SW: Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. (2000) 48(5):723-729.
162. HARRIS RC, SODERLUND K, HULTMAN E: Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin. Sci. (1992) 83:367-374.
163. HULTMAN E, SODERLUND K, TIMMONS JA et al: Muscle creatine loading men. J. Appl. Physiol. (1996) 81:232-237.
164. GREENHAFF PL, CASEY A, SHORT AH et al.: Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin. Sci. (Colch.) (1993) 84:565-571.
165. VANDENBERGHE K, GORIS M, VAN HECKE P et al.: Long-term creatine intake is beneficial to muscle performance during resistance training. J. Appl. Physiol. (1997) 83:2055-2063.
166. GREENHAFF PL, BODIN K, SODERLUND K, HULTMAN E: Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am. J. Physiol. (1994) 266:E725-E730.
167. VANDENBERGHE K, VAN HECKE P, VAN LEEMPUTTE M et al.: Phosphocreatine resynthesis is not affected by creatine loading. Med. Sci. Sports Exerc. (1999) 31:236-242.
168. MIHIC S, MACDONALD JR, MCKENZIE S, TARNOPOLSKY MA: Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med. Sci. Sports Exerc. (2000) 32:291-296.
169. GORDON A, HULTMAN E, KIJSER L et al.: Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc. Res. (1995) 30:413-418.
170. KOSHY KM, GRISWOLD E, SCHNEEBERGER EE: Interstitial nephritis in a patient taking creatine. N. Engl. J. Med. (1999) 340:814-815 (Letter).
171. PRITCHARD NR, KALRA PA: Renal dysfunction accompanying oral creatine supplements. Lancet (1998) 351:1252-1253.
172. POORTMANS JR, AUQUIER H, RENAUT V et al.: Effect of short-term creatine supplementation on renal responses in men. Eur. J. Appl. Physiol. (1997) 76:566-567.
173. POORTMANS JR, FRANCAUX M: Long-term oral creatine supplementation does not impair renal function in healthy athletes. Med. Sci. Sports Exerc. (1999) 31:1108-1110.
174. VAHEDI K, DOMIGO V, AMARENCO P, BOUSSER MG: Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. J. Neurol. Neurosurg. Psychiatry (2000) 68:112-113.
175. LEE MK, CHENG BW, CHE CT, HSIEH DP: Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol. Sci. (2000) 56:424-430.
176. GRUNLER J, ERICSSON J, DALLNER G: Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim. Biophys. Acta (1994) 1212(3):259-277.
177. 10). Biomedical, Functional, Medical, and Therapeutic Aspects in Human Health and Diseases (Volume 1). Ebadi M, Marwah J, Chopra R (Eds), Prominent Press, Scottsdale, USA (2001):231-345.
178. 10) on muscular dystrophies and neurogenic atrophies. Biochim. Biophys. Acta (1995) 1271(1):281-286.
179. 10 and vitamin B6 status. Biofactors (1999) 9(2-4):359-363.
180. 10 and vitamin B6. Res. Commun. Chem. Pathol. Pharmacol. (1980) 28(1):145-152.
181. NESS GC, CHAMBERS CM: Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc. Soc. Exp. Biol. Med. (2000) 224:8-19.
182. NESS GC, ZHAO Z, WIGGINS L: Insulin and glucagon modulate hepatic 3-hydroxy-3-methylglutaryl- coenzyme A reductase activity by affecting immunoreactive protein levels. J. Biol. Chem. (1994) 269:29168-29172.
183. CHARIOT P, ABADIA P, AGNUS D, DANAN C, CHARPENTIER C, GHERARDI RK: Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. (1993) 94:109-110.
184. 10 during treatment with HMG-CoA reductase inhibitors. Mol. Aspects Med. (1997) 18(Suppl.):S137-S144.
185. NAMBUDIRI AM, RANGANATHAN S, RUDNEY H: The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the regulation of ubiquinone synthesis in human fibroblasts. J. Biol. Chem. (1980) 255:5894-5899.
186. WALRAVENS PA, GREENE C, FRERMAN FE: Lovastatin, isoprenes, and myopathy. Lancet (1989) 2:1097-1098.
187. DE PINIEUX G, CHARIOT P, AMMISAID M et al.: Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. (1996) 42:333-337.
188. GHIRLANDA G, ORADEI A, MANTO A et al.: Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. (1993) 33:226-229.
189. LAAKSONEN R, JOKELAINEN K, LAAKSO J et al.: The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. (1996) 77:851-854.
190. LAAKSONEN R, JOKELAINEN K, SAHI T, TIKKANEN MJ, HIMBERG JJ: Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Pharmacol. Ther. (1995) 57:62-66.
191. THIBAULT A, SAMID D, TOMPKINS AC et al.: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. (1996) 2:483-491.
192. BAKER SK, VLADUTIU GD, TARNOPOLSKY MA: McArdle disease unmasked by statin exposure. 50th Scientific Meeting of the American Association of Electrodiagnostic Medicine. San Francisco, CA, USA (2003) (In press).
193. ELMBERGER PG, KALEN A, BRUNK UT, DALLNER G: Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile. Lipids (1989) 24:919-930.
194. 10, alpha-tocopherol and free cholesterol in HDL and LDL fractions. Ann. Med. (1991) 23:649-656.
195. LAAKSONEN R, OJALA JP, TIKKANEN MJ, HIMBERG JJ: Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. (1994) 46:313-317.
196. 1 complex stability in yeast coq mutants. J. Biol. Chem. (2002) 277(13):10973-10981.
197. ZHANG Y, ABERG F, APPELKVIST EL, DALLNER G, ERNSTER L: Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. (1995) 125(3):446-453.
198. ZHANG Y, TURUNEN M, APPELKVIST EL: Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells. J. Nutr. (1996) 126(9):2089-2097.
199. 10 in preventing in vitro doxorubicin-related cardiac damages. Oncology (1988) 45(3):242-246.
200. 10 treatment in serious heart failure. Biofactors (1999) 9(2-4):285-289.
201. RUSTIN P, VON KLEIST-RETZOW JC, CHANTREL-GROUSSARD K, SIDI D, MUNNICH A, ROTIG A: Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet (1999) 354(9177):477-479.
202. BEYER RE: An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem. Cell. Biol. (1992) 70:390-403.
203. ERNSTER L, DALLNER G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta (1995) 1271:195-204.
204. NOACK H, KUBE U, AUGUSTIN W: Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic. Res. (1994) 20:375-386.
205. FORSMARK-ANDREE P, LEE CP, DALLNER G, ERNSTER L: Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic. Biol. Med. (1997) 22:391-400.
206. FREI B, KIM MC, AMES BN: Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. USA (1990) 87(12):4879-4883.
207. 10. Free Radic. Biol. Med. (1999) 26(11-12):1375-1382.
208. LASS A, SOHAL RS: Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. (2000) 14(1):87-94.
209. 10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J. Nutr. (2000) 130(9):2343-2348.
210. 10. J. Am. Coll. Nutr. (2001) 20(6):591-598.
211. ARROYO A, NAVARRO F, GOMEZ-DIAZ C et al.: Interactions between ascorbyl fiee radical and coenzyme Q at the plasma membrane. J. Bioenerg. Biomembr. (2000) 32(2):199-210.
212. KOZLOV AV, GILLE L, STANIEK K, NOHL H: Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch. Biochem. Biophys. (1999) 363(1):148-154.
213. GOTZ ME, DIRR A, BURGER R et al.: Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithio-carbamate. Eur. J. Pharmacol. (1994) 266:291-300.
214. 10 enhances the recovery of human-lymphocytes from oxidative DNA damage. FASEB J. (2001) 15(8):1425-1427.
215. CAMMER W: Protection of cultured oligodendrocytes against tumor necrosis factor-alpha by the antioxidants coenzyme Q(10) and N-acetyl cysteine. Brain Res. Bull. (2002) 58(6):587-592.
216. JUURLINK BH, THORBURNE SK, HERTZ L: Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia (1998) 22(4):371-378.
217. SANCHEZ-ALCAZAR JA, SCHNEIDER E, HERNANDEZ-MUNOZ I et al.: Reactive oxygen species mediate the down-regulation of mitochondrial transcripts and proteins by tumour necrosis factor-alpha in L929 cells. Biochem. J. (2003) 370(Pt 2):609-619.
218. VILLALBA JM, NAVAS P: Plasma membrane redox system in the control of stress-induced apoptosis. Antioxid. Redox Signal. (2000) 2(2):213-230.
219. 2+-reversible inhibition of the mitochondrial megachannel by ubiquinone analogues. FEBS Lett. (2000) 480(2-3):89-94.
220. WALTER L, MIYOSHI H, LEVERVE X, BERNARD P, FONTAINE E: Regulation of the mitochondrial permeability transition pore by ubiquinone analogs. A progress report. Free Radic. Res. (2002) 36(4):405-412.
221. 10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. (2003) 278(30):28220-28228.
222. FERNANDEZ-AYALA DJ, MARTIN SF, BARROSO MP et al.: Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid. Redox Signal. (2000) 2(2):263-275.
223. NAVAS P, FERNANDEZ-AYALA DM, MARTIN SF et al.: Ceramide-dependent caspase 3 activation is prevented by coenzyme Q from plasma membrane in serum-deprived cells. Free Radic. Res. (2002) 36(4):369-374.
224. 10 deficiency. Neurology (2001) 57:515-518.
225. 10 at rostral ventrolateral medulla against fatality during experimental endotoxemia in the rat. Shock (2003) 19(5 ):427-432.
226. 10 in redox signaling and inhibition of death signaling in the rat heart mitochondria. Antioxid. Redox Signal. (2001) 3(1):103-112.
227. 10: effect of CoQ10 supplementation on human skeletal muscle. Free Radic. Res. (2002) 36(4):445-453.
228. ECHTAY KS, WINKLER E, KLINGENBERG M: Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature (2000) 408(6812):609-613.
229. CASTEILLA L, RIGOULET M, PENICAUD L: Mitochondrial ROS metabolism: modulation by uncoupling proteins. IUBMB Life (2001) 52(3-5):181-188.
230. SCHRAUWEN P, HESSELINK M: UCP2 and UCP3 in muscle controlling body metabolism. J. Exp. Biol. (2002) 205(Pt 15):2275-2285.
231. ECHTAY KS, WINKLER E, FRISCHMUTH K, KLINGENBERG M: Uncoupling proteins 2 and 3 are highly active H(+) transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone). Proc. Natl. Acad. Sci. USA (2001) 98(4):1416-1421.
232. ECHTAY KS, ROUSSEL D, ST-PIERRE J et al.: Superoxide activates mitochondrial uncoupling proteins. Nature (2002) 415(6867):96-99.
233. 10 administration and its potential for treatment of neurodegenerative diseases. Biofactors (1999) 9(2-4):261-266.
234. 10 as a possible treatment for neurodegenerative diseases. Free Radic. Res. (2002) 36(4):455-460.
235. 10 during reperfusion of ischemic limbs. Mol. Aspects Med. (1994) 15(Suppl. ):S177-S185.
236. 10 improves reoxygenation-induced recovery of cardiac contractile force after hypoxia. J. Pharmacol. Exp. Ther. (1987) 243(3):1131-1138.
237. 10 supplementation on mitochondrial function after myocardial ischemia reperfusion. J. Surg. Res. (2002) 102(2):221-228.
238. OSTROWSKI RP: Effect of coenzyme Q(10) on biochemical and morphological changes in experimental ischemia in the rat brain. Brain Res. Bull. (2000) 53(4):399-407.
239. 10. Neurosci. Lett. (1994) 177(1-2):58-62.
240. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. (1994) 36(6):882-888.
241. SCHULZ JB, MATTHEWS RT, HENSHAW DR, BEAL MF: Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience (1996) 71(4):1043-1048.
242. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA (1998) 95(15):8892-8897.
243. 10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. (2001) 315(3):149-153.
244. 10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. (2002) 22(5):1592-1599.
245. 10. J. Neurosci. Res. (2003) 72(6):691-703.
246. AKANEYA Y, TAKAHASHI M, HATANAKA H: Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture. Neurosci. Lett. (1995) 193(1):53-56.
247. 10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. (1998) 783(1):109-114.
248. HASEGAWA E, TAKESHIGE K, OISHI T, MURAI Y, MINAKAMI S: 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. (1990) 170(3):1049-1055.
249. 10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. (1995) 132(2):279-283.
250. FALON J, MATTHEWS RT, HYMAN BT, BEAL MF: MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Exp. Neurol. (1997) 144(1):193-198.
251. 10 tolerability in Huntington's disease. Mov. Disord. (1996) 11(3):321-323.
252. RANEN NG, PEYSER CE, COYLE JT et al.: A controlled trial of idebenone in Huntington's disease. Mov. Disord. (1996) 11(5):549-554.
253. 10 and remacemide in Huntington's disease. Neurology (2001) 57(3):397-404.
254. 10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. (2001) 10(3-4):224-253.
255. JENNER P: Oxidative stress in Parkinson's disease. Ann. Neurol. (2003) 53(Suppl. 3):S26-S36.
256. HIRSCH EC, BRANDEL JP, GALLE P, JAVOY-AGID F, AGID Y: Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. (1991) 56(2):446-451.
257. GOOD PF, OLANOW CW, PERL DP: Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. (1992) 593(2):343-346.
258. SIAN J, DEXTER DT, LEES AJ et al.: Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. (1994) 36(3):348-355.
259. ALBANO CB, MURALIKRISHNAN D, EBADI M: Distribution of coenzyme Q homologues in brain. Neurochem. Res. (2002) 27(5):359-368.
260. MCGUIRE SO, LING ZD, LIPTON JW, SORTWELL CE, COLLIER TJ, CARVEY PM: Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. (2001) 169(2):219-230.
261. SCHAPIRA AH, COOPER JM, DEXTER D, CLARK JB, JENNER P, MARSDEN CD: Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. (1990) 54(3):823-827.
262. SCHAPIRA AH, MANN VM, COOPER JM et al.: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. (1990) 55(6):2142-2145.
263. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. (1997) 42(2):261-264.
264. 10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch. Neurol. (2002) 59(10):1541-1550.
265. 10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci. Lett. (2003) 341:201-201.
266. OGASAHARA S, ENGEL AG, FRENS D, MACK D: Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc. Natl. Acad. Sci. USA (1989) 86(7):2379-2382.
267. 10 deficiency. Lancet (2000) 356(9227):391-395.
268. 10 deficiency. Neurology (2001) 56(7):849-855.
269. VAN MALDERGEM L, TRIJBELS F, DIMAURO S et al.: Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann. Neurol. (2002) 52(6):750-754.
270. SERVIDEI S, SPINAZZOLA A, CROCIANIP et al: Replacement therapy is is effective in familial mitochondrial encephalomyopathy with muscle CoQ10 deficiency. Neurology (1996) 46:A420.
271. 10 deficiency. Neurology (2003) 60(7):1206-1208.
272. 10 deficiency J. Pediatr. (2001) 139(3):456-458.
273. 10 in Kearns-Sayre syndrome. Neurology (1985) 35(3):372-377.
274. 10 in mitochondrial encephalomyopathies. Neuromuscul. Disord. (1991) 1(6):443-447.
275. CHAN TS, TENG S, WILSON JX, GALATI G, KHAN S, O'BRIEN PJ: Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1 (NQO1). Free Radic. Res. (2002) 36(4):421-427.
276. 10. Neurology (1986) 36(1):45-53.
277. 10 and multiple vitamins in a patient with bilateral optic neuropathy. Mov. Disord. (1999) 14(5):855-859.
278. 31P NMR study. Neurology (1989) 39(3):399-403.
279. 10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia (1998) 41(5):584-588.
280. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology (1992) 42(6):1203-1208.
281. IKEJIRI Y, MORI E, ISHII K, NISHIMOTO K, YASUDA M, SASAKI M: Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology (1996) 47(2):583-585.
282. LIOU CW, HUANG CC, LIN TK, TSAI JL, WEI YH: Correction of pancreatic beta-cell dysfunction with coenzyme Q(10) in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome and diabetes mellitus. Eur. Neurol. (2000) 43(1):54-55.
283. 10 treatment of leber hereditary optic neuropathy. J. Neuroophthalmol. (2002) 22(1):66.
284. MASHIMA Y, KIGASAWA K, WAKAKURA M, OGUCHI Y: Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J. Neuroophthalmol. (2000) 20(3):166-170.
285. BRESOLIN N, DORIGUZZI C, PONZETTO C et al.: Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J. Neurol. Sci. (1990) 100(1-2):70-78.
286. 10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur. Neurol. (1997) 37(4):212-218.
287. HAUSSE AO, AGGOUN Y, BONNET D et al.: Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart (2002) 87(4):346-349.
288. RUSTIN P, ROTIG A, MUNNICH A, SIDI D: Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res. (2002) 36(4):467-469.
289. BUYSE G, MERTENS L, DI SALVO G et al.: Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology (2003) 60(10):1679-1681.
290. MARIOTTI C, SOLARI A, TORTA D, MARANO L, FIORENTINI C, DI DONATO S: Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology (2003) 60(10):1676-1679.
291. SORESCU D, GRIENDLING KK: Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Fail. (2002) 8(3):132-140.
292. LODI R, HART PE, RAJAGOPALAN B et al.: Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreichs ataxia. Ann. Neurol. (2001) 49(5):590-596.
293. SCHOLS L, VOGERD M, SCHILLINGS M, SKIPKA G, ZANGE J: Idebenone in patients with Friedreich ataxia. Neurosci. Lett. (2001) 306(3):169-172.
294. MARANGON K, DEVARAJ S, TIROSH O et al.: Comparison of the effect of alpha-lipoic add and alpha-tocopherol supplementation on measures of oxidative stress. Free Radic. Biol. Med. (1999) 27:1114-1121.
295. 1-antiproteinase inactivation by oxidized and reduced lipoic acid. FEBS Lett. (1996) 379:74-76.
296. WOLZ P, KRIEGLSTEIN J: Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology (1996) 35:369-375.
297. HAGEN TM, INGERSOLL RT, LYKKESFELDT J et al.: (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. (1999) 13:411-418.
298. BURKE D, CHILIBECK P, PARISE G, TARNOPOLSKY M, CANDOW D: The effect of a-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Sport Nutr. Exerc. Met. (2003) (In press).
299. MIDAOUI AE, ELIMADI A, WU L, HADDAD PS, DE CHAMPLAIN J: Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am. J. Hypertens. (2003) 16(3):173-179.
300. BARBIROLI B, MEDORI R, TRITSCHLER HJ et al.: Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J. Neurol. (1995) 242:472-477.
301. HAAK E, USADEL KH, KUSTERER K et al.: Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy Exp. Clin. Endocrinol. Diabetes (2000) 108:168-174.
302. ANDRONE L, GAVAN NA, VERESIU IA, ORASAN R: In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In vivo (2000) 14:327-330.
303. ZIEGLER D, HANEFELD M, RUHNAU KJ et al.: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia (1995) 38(12):1425-1433.
304. RELJANOVIC M, REICHEL G, RETT K et al.: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic. Res. (1999) 31(3):171-179.
305. ZIEGLER D, HANEFELD M, RUHNAU KJ et al.: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care (1999) 22(8):1296-1301.
306. AMETOV AS, BARINOV A, DYCK PJ et al.: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care (2003) 26(3):770-776.
307. RUHNAU KJ, MEISSNER HP, FINN JR et al.: Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med. (1999) 16(12):1040-1043.
308. ZIEGLER D, RELJANOVIC M, MEHNERT H, GRIES FA: Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes (1999) 107(7):421-430.
309. GALLAGHER PM, CARRITHERS JA, GODARD MP, SCHULZE KE, TRAPPE SW: Beta-hydroxy-beta-methylbutyrate ingestion, Part I: effects on strength and fat free mass. Med. Sci. Sports Exerc. (2000) 32(12):2109-2115.
310. GALLAGHER PM, CARRITHERS JA, GODARD MP, SCHULZE KE, TRAPPE SW: Beta-hydroxy-beta-methylbutyrate ingestion, part II: effects on hematology, hepatic and renal function. Med. Sci. Sports Exerc. (2000) 32(12):2116-2119.
311. MAY PE, BARBER A, D'OLIMPIO JT, HOURIHANE A, ABUMRAD NN: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. (2002) 183(4):471-479.
312. CLARK RH, FELEKE D, DIN M et al.: Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J. Parenter. Enteral Nutr. (2000) 24(3):133-139.
313. VUKOVICH MD, STUBBS NB, BOHLKEN RM: Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. J. Nutr. (2001) 131(7):2049-2052.
314. PANTON LB, RATHMACHER JA, BAIER S, NISSEN S: Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Nutrition (2000) 16(9):734-739.
315. KNITTER AE, PANTON L, RATHMACHER JA, PETERSEN A, SHARP R: Effects of beta-hydroxy-beta-methylbutyrate on muscle damage after a prolonged run. J. Appl. Physiol. (2000) 89(4):1340-1344.
316. NISSEN S, SHARP RL, PANTON L, VUKOVICH M, TRAPPE S, FULLER JC Jr: β-Hydroxy-β-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. J. Nutr. (2000) 130(8):1937-1945.
317. ELIASSON MJL, SAMPEI K, MANDIR AS et al: Poly(ADP-ribose) polymerase gene disruption renders mice resistent to cerebral ischemia. Nat. Med. (1997) 3:1089-1095.
318. AYOUB IA, LEE EJ, OGILVY CS et al: Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci. Lett. (1999) 259:21-24.
319. MANDIR AS, PRZEDBORSKI S, JACKSON-LEWIS V et al.: Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. USA (1999) 96:5774-5779.
320. COSI C, MARIEN M: Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res. (1998) 809:58-67.
321. + levels in ischemic core and penumbra. Neurochem. Res. (2003) 28(8):1227-1234.
322. + and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. Life Sci. (1996) 58:691-699.
323. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology (1992) 42:2147-2152.
324. BERNSEN PLJA, GABREELS FJM, RUITENBEEK W, HAMBURGER HL: Treatment of complex I defiency with riboflavin. J. Neurol. Sci. (1993) 118:181-187.
325. OGLE RF, CHRISTODOULOU J, FAGAN E et al.: Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin. J. Pediatr. (1997) 130:138-145.
326. SCHOLTE HR, BUSCH HF, BAKKER HD et al.: Riboflavin-responsive complex I deficiency. Biochim. Biophys. Acta (1995) 1271:75-83.
327. ANTOZZI C, GARAVAGLIA B, MORA M et al.: Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency. Neurology (1994) 44:2153-2158.
328. PELUCHETTI D, ANTOZZI C, ROI S et al.: Riboflavin responsive multiple acyl-CoA dehydrogenase deficiency: functional evaluation of recovery after high dose vitamin supplementation. J. Neurol. Sci. (1991) 105:93-98.
329. VERGANI L, BARILE M, ANGELINI C et al.: Riboflavin therapy. Biochemical heterogeneity in two adult lipid storage myopathies. Brain (1999) 122:2401-2411.
330. PARKINSON STUDY GROUP: Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med. (1989) 321:1364-1371.